Direct medical costs for patients with tuberous sclerosis complex and surgical resection of subependymal giant cell astrocytoma: a US national cohort study

References

• Sun P, Kohrman M, Liu J, et al. Outcomes of resecting subependymal giant cell astrocytoma (SEGA) among patients with SEGA-related tuberous sclerosis complex: a national claims database analysis. Curr Med Res Opin 2012;28:657-63
   PubMed Web of Science ®Google Scholar
• Sun P, Krueger D, Liu J, et al. Surgical resection of subependymal giant cell astrocytomas (SEGAs) and changes in SEGA-related conditions: a US national claims database study. Curr Med Res Opin 2012;28:651-6
   PubMed Web of Science ®Google Scholar
• Ahmad Z, Rauf F, Azad NS, et al. Subependymal giant cell astrocytoma. J Pak Med Assoc Oct 2006;56:463-5
   PubMedGoogle Scholar
• Kumar R, Singh V. Subependymal giant cell astrocytoma: a report of five cases. Neurosurg Rev 2004;27:274-80
   Google Scholar
• Di Rocco C, Iannelli A, Marchese E. On the treatment of subependymal giant cell astrocytomas and associated hydrocephalus in tuberous sclerosis. Pediatr Neurosurg 1995;23:115-21
   PubMed Web of Science ®Google Scholar
• Sinson G, Sutton LN, Yachnis AT, et al. Subependymal giant cell astrocytomas in children. Pediatr Neurosurg 1994;20:233-9
   PubMed Web of Science ®Google Scholar
• Sugita Y, Taguchi A, Miyagi J, et al. The cystic growth of a subependymal giant-cell astrocytoma with tuberous sclerosis. Kurume Med J 1992;39:123-8
   Google Scholar
• Hallett L, Foster T, Liu Z, et al. Burden of disease and unmet needs in tuberous sclerosis complex with neurological manifestations: systematic review. Curr Med Res Opin 2011;27:1571-83
   PubMed Web of Science ®Google Scholar
• Krueger DA, Care MM, Holland K, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 2010;363:1801-11
   PubMed Web of Science ®Google Scholar
• Kwiatkowski D, Whittenmore V, Thiele E, eds. Tuberous sclerosis complex: genes, clinical features and therapeutics. New York, NY: Wiley-BlackWell, 2010
   Google Scholar
• NINDS. Tuberous Sclerosis Fact Sheet. 2010. http://www.ninds.nih.gov/disorders/tuberous_sclerosis/detail_tuberous_sclerosis.htm#one. Accessed June 22, 2010
   Google Scholar
• Yates JR. Tuberous sclerosis. Eur J Hum Genet 2006;14:1065-73
   PubMed Web of Science ®Google Scholar
• Chung TK, Lynch ER, Fiser CJ, et al. Psychiatric comorbidity and treatment response in patients with tuberous sclerosis complex. Ann Clin Psychiatry Off J Am Acad Clin Psychiatrists 2011;23:263-9
   Google Scholar
• Tsai P, Sahin M. Mechanisms of neurocognitive dysfunction and therapeutic considerations in tuberous sclerosis complex. Curr Opin Neurol 2011;24:106-13
   Google Scholar
• de Vries PJ, Hunt A, Bolton PF. The psychopathologies of children and adolescents with tuberous sclerosis complex (TSC): a postal survey of UK families. Eur Child Adolesc Psychiatry 2007;16:16-24
   PubMed Web of Science ®Google Scholar
• Rok P, Kasprzyk-Obara J, Domanska-Pakiela D, et al. Clinical symptoms of tuberous sclerosis complex in patients with an identical TSC2 mutation. Med Sci Mon Int Med J Exp Clin Res 2005;11:CR230-4
   Google Scholar
• Neumann HP, Schwarzkopf G, Henske EP. Renal angiomyolipomas, cysts, and cancer in tuberous sclerosis complex. Sem Pediatr Neurol 1998;5:269-75
   PubMedGoogle Scholar
• Rodriguez JA, Evans RL, Daiger SP, et al. Molecular analysis of the human vitamin D binding protein (group specific component, Gc) in tuberous sclerosis complex (TSC). J Med Genet 1997;34:509-11
   Google Scholar
• Ruggieri M, Carbonara C, Magro G, et al. Tuberous sclerosis complex: neonatal deaths in three of four children of consanguineous, non-expressing parents. J Med Genet 1997;34:256-60
   Google Scholar
• Curatolo P. Neurological manifestations of tuberous sclerosis complex. ChNS Off J Int Soc Pediatr Neurosurg 1996;12:515-21
   Google Scholar
• Neumann HP, Bruggen V, Berger DP, et al. Tuberous sclerosis complex with end-stage renal failure. Nephrol Dial Transplant 1995;10:349-53
   PubMed Web of Science ®Google Scholar
• Franz DN, Belousova E, Sparagana S, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2013;381:125-32
   PubMed Web of Science ®Google Scholar
• Amin S, Carter M, Edwards RJ, et al. The outcome of surgical management of subependymal giant cell astrocytoma in tuberous sclerosis complex. EJPN Off J Eur Paediatr Neurol Soc 2013;17:36-44
   PubMed Web of Science ®Google Scholar
• Berhouma M. Management of subependymal giant cell tumors in tuberous sclerosis complex: the neurosurgeon's perspective. World J Pediatr 2010;6:103-10
   PubMed Web of Science ®Google Scholar
• Chan JA, Zhang H, Roberts PS, et al. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation. J Neuropathol Exp Neurol 2004;63:1236-42
   PubMed Web of Science ®Google Scholar
• Goh S, Butler W, Thiele EA. Subependymal giant cell tumors in tuberous sclerosis complex. Neurology 2004;63:1457-61
   PubMed Web of Science ®Google Scholar
• Ozek MM, Ozek E, Pamir MN, et al. Subependymal giant cell astrocytomas in tuberous sclerosis. Turk J Pediatr A 1993;35:145-50
   PubMed Web of Science ®Google Scholar
• Park KJ, Kano H, Kondziolka D, et al. Gamma Knife surgery for subependymal giant cell astrocytomas. Clinical article. J Neurosurg 2011;114:808-13
   Google Scholar
• Ekici MA, Kumandas S, Per H, et al. Surgical Timing of the Subependymal Giant Cell Astrocytoma (SEGA) with the Patients of Tuberous Sclerosis Complex. Turk Neurosurg 2011;21:315-24
   PubMed Web of Science ®Google Scholar
• Pascual-Castroviejo I, Pascual-Pascual SI, Velazquez-Fragua R, et al. [Subependymal giant cell astrocytoma in tuberous sclerosis complex. A presentation of eight paediatric patients]. Neurologia 2010;25:314-21
   PubMed Web of Science ®Google Scholar
• Cai R, Di X. Combined intra- and extra-endoscopic techniques for aggressive resection of subependymal giant cell astrocytomas. World Neurosurg 2010;73:713-18
   PubMedGoogle Scholar
• Bongiorni L, Arroyo HA, Lubienicki F. [Subependymal nodules-sudependymal giant cell astrocytoma complex in children with tuberous sclerosis]. Medicina (B Aires) 2009;69:8-14
   PubMed Web of Science ®Google Scholar
• Phi JH, Park SH, Chae JH, et al. Congenital subependymal giant cell astrocytoma: clinical considerations and expression of radial glial cell markers in giant cells. ChNS Off J Int Soc Pediatr Neurosurg 2008;24:1499-503
   Google Scholar
• de Ribaupierre S, Dorfmuller G, Bulteau C, et al. Subependymal giant-cell astrocytomas in pediatric tuberous sclerosis disease: when should we operate? Neurosurgery 2007;60:83-9; discussion 89–90
   PubMed Web of Science ®Google Scholar
• Sharma M, Ralte A, Arora R, et al. Subependymal giant cell astrocytoma: a clinicopathological study of 23 cases with special emphasis on proliferative markers and expression of p53 and retinoblastoma gene proteins. Pathology 2004;36:139-44
   PubMed Web of Science ®Google Scholar
• Kim SK, Wang KC, Cho BK, et al. Biological behavior and tumorigenesis of subependymal giant cell astrocytomas. J Neurooncol 2001;52:217-25
   PubMed Web of Science ®Google Scholar
• Levine NB, Collins J, Franz DN, et al. Gradual formation of an operative corridor by balloon dilation for resection of subependymal giant cell astrocytomas in children with tuberous sclerosis: specialized minimal access technique of balloon dilation. Minim Invasive Neurosurg 2006;49:317-20
   PubMed Web of Science ®Google Scholar
• Severens JL, Milne RJ. Discounting health outcomes in economic evaluation: the ongoing debate. Value Health J Inte Soc Pharmacoecon Outcomes Res 2004;7:397-401
   Google Scholar